PT  - JOURNAL ARTICLE
AU  - TOMISAKI, IKKO
AU  - HARADA, MIRII
AU  - SAKANO, SHIGERU
AU  - TERADO, MICHIKAZU
AU  - HAMASUNA, RYOICHI
AU  - HARADA, SHUJI
AU  - MATSUMOTO, HIROOMI
AU  - AKASAKA, SOICHIRO
AU  - NAGATA, YUJIRO
AU  - MINATO, AKINORI
AU  - HARADA, KEN-ICHI
AU  - FUJIMOTO, NAOHIRO
TI  - Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
AID  - 10.21873/anticanres.16159
DP  - 2023 Jan 01
TA  - Anticancer Research
PG  - 269--274
VI  - 43
IP  - 1
4099  - http://ar.iiarjournals.org/content/43/1/269.short
4100  - http://ar.iiarjournals.org/content/43/1/269.full
SO  - Anticancer Res2023 Jan 01; 43
AB  - Background/Aim: We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC). Patients and Methods: We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab after chemotherapy between March 2018 and December 2021. Patients were divided according to BMI into the non-overweight group (BMI <25 kg/m2) and the overweight group (BMI ≥25 kg/m2). We compared the two groups’ tumour response, survival rates, and incidence of immune-related adverse events (irAEs) and investigated the factors predicting survival. Results: Of 84 eligible patients, 63 (75%) and 21 (25%) were in the non-overweight and overweight groups, respectively. Although the objective response rate was higher in the overweight group (55%) than that in the non-overweight group (29%), the difference was not significant. Progression-free survival (PFS) was significantly longer in the overweight group (median 15.2 months) than that in the non-overweight group (median 4.8 months; p=0.01). Overall survival was also longer in the overweight group (median 36.1 months) compared to that in the non-overweight group (13.4 months), but the difference was not significant (p=0.11). Multivariable analysis showed that overweight was significantly associated with favourable PFS. Any and severe (grade 3) irAEs were observed in 15 (24%) and 5 (7.9%) patients in the non-overweight group, respectively, and in 8 (38%) and 2 (9.5%) patients in the overweight group, respectively, but the differences were not significant. Conclusion: BMI was associated with oncological outcomes in patients with advanced UC who received pembrolizumab but not with the development of irAEs.